Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galinpepimut-S in Malignant Pleural Mesothelioma
NCT01265433Phase 2Completed
- Sponsor
- SELLAS Life Sciences Group, Inc.
- Start
- Dec 2010
- Primary completion
- Nov 2016
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of galinpepimut-s in malignant pleural mesothelioma (MPM) (2 arms), sponsored by SELLAS Life Sciences Group, Inc. Primary endpoints: 1-year Progression-free Survival and Progression-free Survival. Started Dec 2010; status: completed.
02
Drugs
galinpepimut-s
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT01265433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01265433.